Preclinical toxicity studies supporting 2DG for treatment of status epilepticus

Thomas P Sutula1, Nathan B Fountain2

  • 1Department of Neurology, University of Wisconsin, Madison WI, USA; Hexokine Therapeutics, Inc. Madison WI, USA.

Epilepsy & Behavior : E&B
|September 6, 2024
PubMed